DR NEERGAARDS VEJ 5F, HOERSHOLM, G7
Announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Reports sustained clinical responses for all patients at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Will present new immune data for personalized cancer vaccine EVX-01 at the SITC 2026 Annual Meeting
Applies Its AI-Immunology™ Platform in Autoimmune Diseases
Announces Amendment to Articles of Association and Sale of American Depositary Shares
Reports Unaudited Condensed Consolidated Interim Financial Statements for the Period Ended June 30, 2026
Announces Business Update and Second Quarter 2026 Financial Results
Expands and Refocuses R&D Pipeline with EVX-05, an AI-Designed Off-the-Shelf Brain Cancer Vaccine Program
Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities of Certain Foreign Private Issuers
Effectiveness Notice
Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis
Prospectus filed pursuant to Rule 424(b)(4)
Amended Registration Statement for Securities of Certain Foreign Private Issuers
No filings found
Initial Statement of Beneficial Ownership
Amended Initial Statement of Beneficial Ownership
Correspondence
Submission Upload